DDW Editor Reece Armstrong speaks to Elke Bestel, Chief Medical Officer at Igyxos, about the treatment space for infertility and how the company’s monoclonal antibody IGX12 could represent a differentiated approach.   RA: Why have treatments for infertility remained limited?  EB: Developing treatments for infertility has been and is still complex. First of all, infertility can result from hormonal, anatomical, metabolic, genetic, immune and environmental factors, and often […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!